Showing 1441-1450 of 4065 results for "".
New-Onset Ketosis-Prone Diabetes in an Adult with Spinal Muscular Atrophy Type III
https://reachmd.com/programs/neurofrontiers/new-onset-ketosis-prone-diabetes-in-an-adult-with-spinal-muscular-atrophy-type-iii/36615/Women in Aesthetics: Divya Gugnani of Wander Beauty
https://reachmd.com/topics/skincare/women-in-aesthetics-divya-gugnani-of-wander-beauty/35222/Mobilization Outcomes After Aneurysmal Subarachnoid Hemorrhage
https://reachmd.com/programs/neurofrontiers/mobilization-outcomes-after-aneurysmal-subarachnoid-hemorrhage/57157/Targeting NETs: A New Frontier in COPD Treatment
https://reachmd.com/programs/clinicians-roundtable/targeting-nets-a-new-frontier-in-copd-treatment/26396/Here’s how targeting neutrophil extracellular traps can lead to reduced COPD side effects and the development of improved treatments.Addressing Unmet Needs in Metastatic Uveal Melanoma
https://reachmd.com/programs/cme/addressing-unmet-needs-in-metastatic-uveal-melanoma/48980/Dive into what sets metastatic uveal melanoma (mUM) apart from cutaneous melanoma and why that matters for clinical decision-making. Explore how HLA A*02:01 typing informs patient selection and how bispecific TCR therapy is changing the treatment landscape. Real-world cases and clinical trial data bUpdates from MINT: Inebilizumab Reduces Relapses and Rescue Therapy Use
https://reachmd.com/programs/neurofrontiers/updates-from-mint-inebilizumab-reduces-relapses-and-rescue-therapy-use/35869/After the primary findings from the Myasthenia Gravis Inebilizumab Trial (MINT) demonstrated the clinical benefit and safety of inebilizumab for patients with generalized myasthenia gravis (gMG), a secondary analysis evaluated inebilizumab’s impact on exacerbation rates and the need for rescue theraHow I Treat IgA Nephropathy: Lessons From the Case Files
https://reachmd.com/programs/kdigo-conversations-nephrology/title-how-i-treat-iga-nephropathy-lessons-from-the-case-files/37117/Join Dr. Dana Rizk (University of Alabama at Birmingham) as she leads a thought-provoking discussion on applying the updated KDIGO guidelines for IgA nephropathy (IgAN) treatment. She is joined by 2 distinguished guests: Dr. Gaia Coppock (University of Pennsylvania School of Medicine) and Dr. AndreThe Man Who Touched His Own Heart: True Tales of Science, Surgery, and Mystery
https://reachmd.com/programs/book-club/man-who-touched-own-heart-true-tales-science-surgery-mystery/7797/Thought of as the seat of our soul, then as a mysteriously animated object, the heart is still more a mystery than it is understood. Rob Dunn, evolutionary biologist and author of The Man Who Touched His Own Heart, tells the raucous, gory, mesmerizing story of the heart, from the first "explorers" wHow Smart Phones Are Improving Neurologic Care
https://reachmd.com/programs/neurofrontiers/how-smart-phones-are-improving-neurologic-care/6536/Is there an app for helping your patients improve their health? In fact, there are many. Dr. Neil Busis, chief of the division of neurology, department of medicine, at University of Pittsburgh Medical Center Shadyside and Practice and Technology editor of AAN.com, talks with host Dr. Anthony AlessiThe Global Implications of Heparin Contamination
https://reachmd.com/programs/clinicians-roundtable/the-global-implications-of-heparin-contamination/2883/The FDA has issued an extensive recall on several contaminated heparin products, problems which have been traced back to ingredients from China. Dr. Jawed Fareed, professor of pathology and pharmacology at Loyola University Chicago Stritch School of Medicine, takes us through the process of heparin